At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 681 enrolled
Drug / intervention
maribavir +1 moredrug
Likely dose
maribavir 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.
In Brief
A Phase 3 clinical trial evaluating maribavir and placebo for Cytomegalovirus Infections. Completed, enrolled 681 participants across 97 sites in 9 countries.
Detailed Summary
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Infections
CountriesBelgium, Canada, France, Germany, Italy, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionNov 2008
Study CompletionMay 2009
TodayJul 2026
First PostedDec 14, 2006
Enrollment StartDec 13, 2006
Primary CompletionNov 10, 2008
Study CompletionMay 23, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.6 years ago
Interventions
maribavirdrug
100 mg twice daily for up to 12 weeks
placeboother
twice daily for up to 12 weeks